Philip J Mease MD

Director, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health and Clinical Professor University of Washington School of Medicine

Join to View Full Profile

1101 Madison StSte 1000Seattle, WA 98104
Phone+1 206-386-2001
Fax+1 206-386-2083

Education & Training

University of WashingtonFellowship, Rheumatology, 1981 - 1982
University of WashingtonResidency, Internal Medicine, 1977 - 1981
Stanford University School of MedicineClass of 1977

Certifications & Licensure

WA State Medical License 1978 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

LIfetime Achievement Award National Psoriasis Foundation, 2019
America's Top Doctors Castle Connolly, 2008-2014
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

Rituxan With or Without Methotrexate in Psoriatic Arthritis Start of enrollment: 2006 Dec 01
Completed
Phase 1
Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
Completed
Phase 2
Prospective Evaluation of RINCE to Reduce Fibromyalgia Effects - 301 Start of enrollment: 2014 Jul 01
Terminated
Not Applicable
A Long-Term Efficacy and Safety Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis Start of enrollment: 2015 Sep 14
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment.
Atul Deodhar, Alan J Kivitz, Marina Magrey, Jessica A Walsh, Philip J Mease
Rheumatology. 2025-04-01
Effect of Bimekizumab on Patient-Reported Outcomes and Work Productivity in Patients With Psoriatic Arthritis: 1-Year Results From 2 Phase III Studies.
Dafna D Gladman, Philip J Mease, Laure Gossec, M Elaine Husni, Alice B Gottlieb
The Journal of Rheumatology. 2025-03-01
Janus-kinase inhibitor use in immune-mediated inflammatory diseases beyond licensed indications: A scoping review.
Dimitris Challoumas, Cameron Simpson, Matthew Arnold, Philip Mease, Robert Moots
Autoimmunity Reviews. 2025-02-28

Journal Articles

Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
Alice Gottlieb, Philip Mease, Arthritis Care & Research
Dual Inhibition of Tumour Necrosis Factor and Interleukin-17A with ABT-122: Open-Label Long-Term Extension Studies in Rheumatoid Arthritis or Psoriatic Arthritis
Philip Mease, MD, Rheumatology
Pain Mechanisms and Ultrasonic Inflammatory Activity as Prognostic Factors in Patients with Psoriatic Arthritis: A Prospective Cohort Study
Philip Mease, MD, Arthritis Care & Research
Secukinumab Provides Rapid and Sustained Pain Relief in Psoriatic Arthritis over 2 Years: Results from the FUTURE 2 Study
Philip J Mease, Vibeke Strand, BioMed Central
Phase 2 Study of ABT‐122, a TNF‐ and IL‐17A–Targeted Dual Variable Domain Immunoglobulin, in Psoriatic Arthritis with Inadequate Methotrexate Response
Philip Mease, MD, Arthritis & Rheumatology
Join now to see all

Lectures

24-Week Results From the RAPID-PsA Study
Annual European Congress of Rheumatology 2012, Berlin, Germany
24-Week Results From the RAPID-PsA Study
European League Against Rheumatism, Annual European Congress of Rheumatology 2012, Berlin, Germany

Authored Content

Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled TrialOctober 2020

Press Mentions

Aligning Clinical & Patient Perspectives to Strengthen PsA ManagementMarch 28th, 2025
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (Deucravacitinib) Compared with Placebo in Adults with Psoriatic ArthritisMarch 8th, 2025
In the Details: Diagnosing PsA Requires Drilling DownFebruary 26th, 2025
Join now to see all